PURPOSE: Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers, and has a worse prognosis compared with hormone receptor-positive disease. Its unfavorable outcome and the lack of hormonal receptors determine the use of adjuvant chemotherapy as part of the standard treatment for these tumors, although several studies have documented that the current standard combination chemotherapy is suboptimal. Therefore, a new functional taxonomy of breast cancer and new targets for therapeutic development are urgently needed. EXPERIMENTAL DESIGN: In this study, we have analyzed the proteome of TNBC applying a high-throughput proteomics approach to routinely archived formalin-fixed, paraffin-embedded tumor tissues. RESULTS: We have been able to identify and quantify more than 1000 protein groups. Some of these proteins are of outstanding interest in the biology and clinical management of this disease, such as CD44 and PARP1. Moreover, we have characterized some signaling pathways that could be related to TNBC genesis and development. CONCLUSION AND CLINICAL RELEVANCE: Our results open up new avenues for the use of proteomics technologies in clinically relevant studies using archival samples. Shotgun LC-MS/MS studies could serve to discover new biomarkers and may provide clues to the genesis of TNBC and underlying molecular alterations.
PURPOSE: Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers, and has a worse prognosis compared with hormone receptor-positive disease. Its unfavorable outcome and the lack of hormonal receptors determine the use of adjuvant chemotherapy as part of the standard treatment for these tumors, although several studies have documented that the current standard combination chemotherapy is suboptimal. Therefore, a new functional taxonomy of breast cancer and new targets for therapeutic development are urgently needed. EXPERIMENTAL DESIGN: In this study, we have analyzed the proteome of TNBC applying a high-throughput proteomics approach to routinely archived formalin-fixed, paraffin-embedded tumor tissues. RESULTS: We have been able to identify and quantify more than 1000 protein groups. Some of these proteins are of outstanding interest in the biology and clinical management of this disease, such as CD44 and PARP1. Moreover, we have characterized some signaling pathways that could be related to TNBC genesis and development. CONCLUSION AND CLINICAL RELEVANCE: Our results open up new avenues for the use of proteomics technologies in clinically relevant studies using archival samples. Shotgun LC-MS/MS studies could serve to discover new biomarkers and may provide clues to the genesis of TNBC and underlying molecular alterations.
Authors: Xinyu Deng; Morris Kohanfars; Huan Ming Hsu; Puneet Souda; Joe Capri; Julian P Whitelegge; Helena R Chang Journal: Int J Proteomics Date: 2014-11-13
Authors: Angelo Gámez-Pozo; Lucía Trilla-Fuertes; Guillermo Prado-Vázquez; Cristina Chiva; Rocío López-Vacas; Paolo Nanni; Julia Berges-Soria; Jonas Grossmann; Mariana Díaz-Almirón; Eva Ciruelos; Eduard Sabidó; Enrique Espinosa; Juan Ángel Fresno Vara Journal: PLoS One Date: 2017-06-08 Impact factor: 3.240
Authors: J Weißer; Z W Lai; P Bronsert; M Kuehs; V Drendel; S Timme; S Kuesters; C A Jilg; U F Wellner; S Lassmann; M Werner; M L Biniossek; O Schilling Journal: BMC Genomics Date: 2015-07-29 Impact factor: 3.969
Authors: Jürgen Cox; Marco Y Hein; Christian A Luber; Igor Paron; Nagarjuna Nagaraj; Matthias Mann Journal: Mol Cell Proteomics Date: 2014-06-17 Impact factor: 5.911
Authors: Guillermo de Velasco; Lucia Trilla-Fuertes; Angelo Gamez-Pozo; Maria Urbanowicz; Gustavo Ruiz-Ares; Juan M Sepúlveda; Guillermo Prado-Vazquez; Jorge M Arevalillo; Andrea Zapater-Moros; Hilario Navarro; Rocio Lopez-Vacas; Ray Manneh; Irene Otero; Felipe Villacampa; Jesus M Paramio; Juan Angel Fresno Vara; Daniel Castellano Journal: Sci Rep Date: 2017-11-17 Impact factor: 4.379